Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cheung Laboratories

This article was originally published in The Gray Sheet

Executive Summary

Microwave technology manufacturer changes its name to Celsion to reflect the company's underlying purpose - to use focused heat technology to kill cancer cells. The firm recently filed an investigational device exemption with FDA to begin clinical studies of its microwave benign prostatic hyperplasia treatment system, which incorporates a microwave balloon catheter for transurethral microwave heating to shrink the prostate and compress the urethra wall. "The combination of microwave heat and balloon catheter compression creates a natural biological stent in the urethra, providing immediate relief of urinary obstruction," the company explains in an April 27 release
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009980

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel